# A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

> **NCT00961480** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** sitagliptin phosphate (+) metformin hydrochloride
- **DRUG:** Comparator: metformin 500mg
- **DRUG:** Comparator: sitagliptin
- **DRUG:** Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet
- **DRUG:** Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
- **DRUG:** Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
- **DRUG:** Comparator: metformin 1000 mg
- **DRUG:** Comparator: metformin 850 mg

## Key facts

- **NCT ID:** NCT00961480
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00961480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00961480, "A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00961480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*